Literature DB >> 20662867

Uric Acid as prognostic marker in advanced nonischemic dilated cardiomyopathy: comparison with N-terminal pro B-type natriuretic peptide level.

Hyungseop Kim1, Hong-Won Shin, Jihyun Son, Hyuck-Jun Yoon, Hyoung-Seob Park, Yun-Kyeong Cho, Choon-Duk Han, Chang-Wook Nam, Seung-Ho Hur, Yoon-Nyun Kim, Kwon-Bae Kim.   

Abstract

Although uric acid (UA) level has been associated with an increased risk of cardiovascular events, it is unclear whether UA can provide greater prognostic information than N-terminal pro B-type natriuretic peptide (NT-proBNP) in advanced heart failure with nonischemic dilated cardiomyopathy (DCM). UA and NT-proBNP values were obtained from a total of 122 DCM patients. Development of clinical events during follow-up was defined as the composite of cardiac death and readmission for heart failure. During follow-up, there were 18 cardiac events. UA and NT-proBNP values were significantly higher in patients with events. The receiver operating characteristics curve showed the area under the curve for UA was greater than that for NT-proBNP. On multivariate analysis, UA remained the only independent predictor of prognosis. UA concentrations > or =8.7 mg/dL rather than NT-proBNP > or =3800 pg/mL were associated with significantly decreased event-free survival. The authors' findings demonstrated that UA value could be an informative predictor in nonischemic DCM. 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662867     DOI: 10.1111/j.1751-7133.2010.00144.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN: 1527-5299


  9 in total

Review 1.  Uric acid in heart failure: a biomarker or therapeutic target?

Authors:  Marc Kaufman; Maya Guglin
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

2.  Serum uric Acid predicts declining of circulating proangiogenic mononuclear progenitor cells in chronic heart failure patients.

Authors:  Alexander E Berezin; Alexander A Kremzer; Tatyana A Samura; Tatyana A Berezina; Yulia V Martovitskaya
Journal:  J Cardiovasc Thorac Res       Date:  2014-09-30

3.  Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease.

Authors:  Daniel Rob; Josef Marek; Gabriela Dostálová; Lubor Goláň; Aleš Linhart
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

4.  On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure.

Authors:  Ahmad Amin; Mitra Chitsazan; Fatemeh Shiukhi Ahmad Abad; Sepideh Taghavi; Nasim Naderi
Journal:  ESC Heart Fail       Date:  2017-02-17

Review 5.  Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid.

Authors:  Andrea Tedeschi; Piergiuseppe Agostoni; Beatrice Pezzuto; Ugo Corra'; Domenico Scrutinio; Rocco La Gioia; Rosa Raimondo; Andrea Passantino; Massimo F Piepoli
Journal:  Eur J Prev Cardiol       Date:  2020-12       Impact factor: 7.804

6.  Serum Uric Acid and Risk of Chronic Heart Failure: A Systematic Review and Meta-Analysis.

Authors:  Lina Miao; Ming Guo; Deng Pan; Pengfei Chen; Zhuhong Chen; Jie Gao; Yanqiao Yu; Dazhuo Shi; Jianpeng Du
Journal:  Front Med (Lausanne)       Date:  2021-12-14

7.  Changes of serum uric acid and its clinical correlation in children with dilated cardiomyopathy.

Authors:  Ting-Ting Li; Hao-Ying Li; Ji Cheng
Journal:  Transl Pediatr       Date:  2021-12

8.  Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension.

Authors:  Jun Gu; Yu-Qi Fan; Hui-Li Zhang; Jun-Feng Zhang; Chang-Qian Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-02-15       Impact factor: 3.738

9.  The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.

Authors:  Agata Bielecka-Dabrowa; Dimitri P Mikhailidis; Manfredi Rizzo; Stephan von Haehling; Jacek Rysz; Maciej Banach
Journal:  Lipids Health Dis       Date:  2013-04-08       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.